IBS Titan™ Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System Clinical Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT05971394

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05971394
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05971394. Allocation not applicable; no masking; primary purpose treatment. Start 2023-07-17 (actual); primary completion 2026-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
IBS Titan™ Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System Clinical Trial
Condition
Infrapopliteal Lesions
Condition
Critical Limb Ischemia
Intervention (Device)
Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™)
Lead sponsor
Biotyx Medical (Shenzhen) Co., Ltd. (class: industry)
Collaborator
VascuScience GmbH (class: not stated)
Collaborator
Mediolanum Cardio Research (class: other)
Collaborator
Euroimage Research Srl (class: not stated)

Record details

Record id
cardio:ct-nct05971394
Content hash
75578028f71e1180a06449163b674dd7cba66a374da67d1d5b912afa2156be90